Third-Generation EGFR TKI Abivertinib for EGFR T790M–Mutant Non–Small Cell Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study
Clin. Cancer Res 2022 Jan 19;[EPub Ahead of Print], Q Zhou, L Wu, P Hu, T An, J Zhou, L Zhang, XQ Liu, F Luo, X Zheng, Y Cheng, N Yang, J Li, J Feng, B Han, Y Song, K Wang, L Zhang, J Fang, H Zhao, Y Shu, XY Lin, Z Chen, B Gan, WH Xu, W Tang, X Zhang, JJ Yang, X Xu, YL WuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.